Acetylcysteine (Fabrol) in chronic bronchitis--a study in general practice.
The results of this general practice study suggest that acetylcysteine (Fabrol) administered orally for 2 months to patients with chronic bronchitis effectively changes the viscosity and character of sputum with resultant ease of expectoration and cough severity. There was a notable improvement in associated abnormal physical signs such as the presence of rhonchi, crepitations and symptoms including dyspnoea at rest. Tolerability was good, with 81% of patients experiencing no side-effects.
D000111:Acetylcysteine / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D013183:Sputum / Q000032:analysis
D000111:Acetylcysteine